# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-16-697741
Filing Date
2016-08-31
Accepted
2016-08-31 10:22:04
Documents
7
Period of Report
2016-10-06
Effectiveness Date
2016-08-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | d245015ddef14a.htm | DEF 14A | 442868
2 | GRAPHIC | g245015dsp_001.jpg | GRAPHIC | 189606
3 | GRAPHIC | g245015dsp_002.jpg | GRAPHIC | 190287
4 | GRAPHIC | g245015dsp_003.jpg | GRAPHIC | 241138
5 | GRAPHIC | g245015g51o28.jpg | GRAPHIC | 6750
6 | GRAPHIC | g245015g68d40.jpg | GRAPHIC | 7348
7 | GRAPHIC | g245015g82l95.jpg | GRAPHIC | 13033
| Complete submission text file | 0001193125-16-697741.txt |  | 1336719

Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: DEF 14A | Act: 34 | File No.: 000-17988 | Film No.: 161862173
SIC: 2835 In Vitro & In Vivo Diagnostic Substances